VIVUS, Inc. (NASDAQ:VVUS) is scheduled to be announcing its earnings results after the market closes on Tuesday, November 7th. Analysts expect the company to announce earnings of ($0.13) per share for the quarter.

Shares of VIVUS, Inc. (NASDAQ:VVUS) opened at $0.68 on Friday. The company has a current ratio of 5.51, a quick ratio of 5.20 and a debt-to-equity ratio of 40.25. The company has a market capitalization of $72.33, a PE ratio of 2.20 and a beta of 0.82. VIVUS, Inc. has a twelve month low of $0.61 and a twelve month high of $1.47.

ILLEGAL ACTIVITY NOTICE: “VIVUS, Inc. (VVUS) Set to Announce Quarterly Earnings on Tuesday” was originally posted by Daily Political and is the property of of Daily Political. If you are viewing this news story on another domain, it was stolen and republished in violation of U.S. and international copyright laws. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/11/05/vivus-inc-vvus-set-to-announce-quarterly-earnings-on-tuesday.html.

A hedge fund recently raised its stake in VIVUS stock. Northern Trust Corp grew its position in shares of VIVUS, Inc. (NASDAQ:VVUS) by 16.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 275,097 shares of the biopharmaceutical company’s stock after purchasing an additional 39,473 shares during the period. Northern Trust Corp owned approximately 0.26% of VIVUS worth $335,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 36.87% of the company’s stock.

A number of equities research analysts have commented on VVUS shares. Zacks Investment Research raised VIVUS from a “hold” rating to a “buy” rating and set a $1.25 price target on the stock in a report on Thursday, July 27th. ValuEngine cut VIVUS from a “buy” rating to a “hold” rating in a report on Friday, September 1st.

About VIVUS

VIVUS, Inc is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED).

Earnings History for VIVUS (NASDAQ:VVUS)

Receive News & Ratings for VIVUS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.